Epidemiology of oesophagogastric cancer

被引:143
|
作者
Lambert, R. [1 ]
Hainaut, P. [2 ]
机构
[1] Int Agcy Res Canc, Grp Screening, F-69372 Lyon 8, France
[2] Int Agcy Res Canc, Grp Mol Carcinogenesis, F-69372 Lyon 8, France
关键词
oesophageal cancer; stomach cancer; epidemiology; Helicabacter pylori; Barrett's oesophagus; endoscopy;
D O I
10.1016/j.bpg.2007.10.001
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Oesophagogastric cancer occurs in the oesophagus, the oesophagogastric region and the stomach, including the proximal and distal stomach. In 2005, the worldwide burden of oesophagogastric cancer was estimated to be 1500000 new cases (500000 oesophagus and 1000000 stomach). Squamous cell cancer is linked with alcohol and tobacco consumption in Western countries. Its incidence is much higher in regions of Asia with a low-socio-economic status, nutritional deficiencies, poor oral status, carcinogens absorbed with smoked meat, fat-cooked foodstuffs, vegetables containing toxic alkaloids or mycotoxins, and water containing nitrites, nitrates and nitrosamines. Adenocarcinoma develops in the columnar lined oesophagus. Its incidence is still low but there is an increasing trend. The incidence of stomach cancer is decreasing worldwide, but is still high in Japan. Causal factors include Helicobacter pylori infection with atrophic gastritis and a diet poor in fruit and vegetables. Preneoplastic conditions of the oesophagogastric mucosa include erosive oesophagitis in alcoholics, columnar lined oesophagus as a complication of gastro-oesophageal reflux disease, and atrophic gastritis following H. pylori infection.
引用
收藏
页码:921 / 945
页数:25
相关论文
共 50 条
  • [1] Staging of oesophagogastric cancer
    Allum, WH
    [J]. BRITISH JOURNAL OF SURGERY, 1998, 85 (01) : 1 - 2
  • [2] Pharmacotherapy for oesophagogastric cancer
    Jackson, Christopher
    Starling, Naureen
    Chua, Yu Jo
    Cunningham, David
    [J]. DRUGS, 2007, 67 (17) : 2539 - 2556
  • [3] Pharmacotherapy for Oesophagogastric Cancer
    Christopher Jackson
    Naureen Starling
    Yu Jo Chua
    David Cunningham
    [J]. Drugs, 2007, 67 : 2539 - 2556
  • [4] Immunotherapy for oesophagogastric cancer
    Davidson, Michael
    Chau, Ian
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2016, 16 (10) : 1197 - 1207
  • [5] Neoadjuvant therapy for oesophagogastric cancer
    Lordick, F
    Stein, HJ
    Peschel, C
    Siewert, JR
    [J]. BRITISH JOURNAL OF SURGERY, 2004, 91 (05) : 540 - 551
  • [6] Delays in diagnosing oesophagogastric cancer
    Schmidt, JG
    [J]. BRITISH MEDICAL JOURNAL, 1997, 315 (7105): : 426 - 427
  • [7] Site distribution of oesophagogastric cancer
    Byrne, JP
    Mathers, JM
    Parry, JM
    Attwood, SEA
    Bancewicz, J
    Woodman, CBJ
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2002, 55 (03) : 191 - 194
  • [8] Overview of controversies in oesophagogastric cancer
    Cameron, Andrew
    Sjoquist, Katrin M.
    Zalcberg, John R.
    [J]. CANCER FORUM, 2011, 35 (03) : 139 - 141
  • [9] Capecitabine - In advanced gastric or oesophagogastric cancer
    Dhillon, Sohita
    Scott, Lesley J.
    [J]. DRUGS, 2007, 67 (04) : 601 - 610
  • [10] Novel genomic aberrations in oesophagogastric cancer
    Rees, J. R.
    Chin, S.
    Marioni, J. C.
    Caldas, C.
    Save, V.
    Ylstra, B.
    Alderdson, D.
    Hardwick, R. H.
    Fitzgerald, R. C.
    [J]. GUT, 2007, 56 : A73 - A74